Objective: The first aim was to demonstrate a previously hypothesized increased sensitivity of corticostriatal glutamatergic terminals in the rodent with brain iron deficiency (BID), a pathogenetic model of restless legs syndrome (RLS). The second aim was to determine whether these putative hypersensitive terminals could constitute a significant target for drugs effective in RLS, including dopamine agonists (pramipexole and ropinirole) and a 2 d ligands (gabapentin). Methods: A recently introduced in vivo optogenetic-microdialysis approach was used, which allows the measurement of the extracellular concentration of glutamate upon local light-induced stimulation of corticostriatal glutamatergic terminals. The method also allows analysis of the effect of local perfusion of compounds within the same area being sampled for glutamate. Results: BID rats showed hypersensitivity of corticostriatal glutamatergic terminals (lower frequency of optogenetic stimulation to induce glutamate release). Both hypersensitive and control glutamatergic terminals were significant targets for locally perfused pramipexole, ropinirole, and gabapentin, which significantly counteracted optogenetically induced glutamate release. The use of selective antagonists demonstrated the involvement of dopamine D 4 and D 2 receptor subtypes in the effects of pramipexole. Interpretation: Hypersensitivity of corticostriatal glutamatergic terminals can constitute a main pathogenetic mechanism of RLS symptoms. Selective D 4 receptor agonists, by specifically targeting these terminals, should provide a new efficient treatment with fewer secondary effects. ANN NEUROL 2017;82:951-960 R estless legs syndrome (RLS) is a common neurologic disorder 1 characterized by a rest-induced, movementresponsive, mostly nocturnal urge to move the legs commonly associated with periodic leg movements during sleep (PLMS) and hyperarousal. 2-4 Altered dopamine function plays an important role in PLMS symptomatology, which is supported by the remarkable therapeutic response to L-dopa and dopamine receptor agonists (such as pramipexole and ropinirole), and the repeated demonstration of biochemical changes related to the dopamine system. 5 Conversely, glutamate mechanisms seem to be involved in both PLMS and the hyperarousal component of RLS. This is supported by the efficacy of ligands of the a 2 d subunits of the calcium channels (such as gabapentin) for both types of disturbances. 6-8 Thus, a 2 d-containing calcium channels are preferentially localized in neuronal glutamate terminals.
R estless legs syndrome (RLS) is a common neurologic disorder 1 characterized by a rest-induced, movementresponsive, mostly nocturnal urge to move the legs commonly associated with periodic leg movements during sleep (PLMS) and hyperarousal. [2] [3] [4] Altered dopamine function plays an important role in PLMS symptomatology, which is supported by the remarkable therapeutic response to L-dopa and dopamine receptor agonists (such as pramipexole and ropinirole), and the repeated demonstration of biochemical changes related to the dopamine system. 5 Conversely, glutamate mechanisms seem to be involved in both PLMS and the hyperarousal component of RLS. This is supported by the efficacy of ligands of the a 2 d subunits of the calcium channels (such as gabapentin) for both types of disturbances. [6] [7] [8] Thus, a 2 d-containing calcium channels are preferentially localized in neuronal glutamate terminals. 9 The clinical success of dopamine agonists and a 2 d ligands is utterly empirical, and there is no consensus about the identity (receptor subtypes) and localization (neuronal elements, circuits) of their main therapeutic targets. Both supraspinal and spinal mechanisms have been invoked to be involved in the pathophysiology of RLS. 10 Supraspinal mechanisms favor a predominant subcortical, striatal impairment of sensorimotor integration. 11, 12 The striatum is the brain area with the highest dopamine innervation and highest density of dopamine receptors and the main point of interaction of dopamine within the cortical-striatal-thalamic-cortical circuits. Furthermore, the main 2 extrinsic striatal inputs are dopaminergic mesencephalic inputs and glutamatergic cortical, limbic, and thalamic inputs. 13 Brain iron deficiency (BID) is now well recognized as a main initial pathogenetic mechanism in the development of RLS. This is based on extensive research studies using cerebrospinal fluid, autopsy material, and brain imaging indicating reduced regional brain iron content, 5, 14 and is further supported by the efficacy of iron therapy for RLS, 6, 8, 15, 16 including RLS refractory to other treatments. 17 Animal models have established a causal relation between BID and altered dopamine function in RLS. BID during the postweaning period in rats or mice produces changes in the dopamine system that parallel those found in RLS, therefore representing a valuable pathophysiological model of RLS (see Discussion). 18 We have recently shown that the brain irondeficient rodent is associated with specific alterations in adenosine neurotransmission that can provide a pathogenetic link between BID and the glutamate mechanisms involved in the PLMS and hyperarousal of RLS. 19, 20 Those include changes in the density of striatal adenosine receptors that modulate corticostriatal glutamate release, which would be expected to increase the sensitivity of corticostriatal glutamatergic neurotransmission. We therefore postulated that an increased sensitivity of corticostriatal glutamatergic neurotransmission can be a pathogenetic factor in the development of PLMS in RLS. 8, 19 Using a recently introduced in vivo optogeneticmicrodialysis approach, 21, 22 we can now demonstrate the existence of hypersensitivity of corticostriatal glutamatergic terminals in rodents with BID. Significantly, hypersensitive and control glutamatergic terminals were targeted by pramipexole, ropinirole, and gabapentin. Using specific dopamine receptor antagonists, we demonstrate the involvement of D 2 and D 4 receptors (D2R and D4R) in the effect of pramipexole, specially indicating that D4R-selective agonists may provide a better treatment for RLS.
Materials and Methods

Animals
Male Sprague-Dawley albino rats (Charles River Laboratories, Wilmington, MA), weighing 80 to 100g and 250 to 350g at the time of the first and second surgeries, respectively, were used in the experiments. Animals were housed 2 per cage and kept on a 12/12-hour dark/light cycle with food and water available ad libitum. All animals used in the study were maintained in accordance with the guidelines of the National Institutes of Health on animal care, and the animal research conducted to perform this study was approved by the National 
Assessment of Systemic and Brain Iron Deficiency
Systemic iron deficiency was assessed by measuring the hematocrit content from blood collected before perfusion at the end of the microdialysis experiments. Blood was collected in heparincoated capillary glass tubes, and hematocrit content was measured after centrifugation. As in previous studies, BID was assessed by analyzing the density of transferrin receptor (TfR) in the brain (lateral striatum) by Western blot, as described in detail elsewhere. 19 It is well established that an increase in TfR density in the brain constitutes a reliable indicator of chronic exposure to low levels of iron in the brain. 23, 24 Because tissue processing used for viral vector expression assessment prevents the use of the Western blot technique, the efficacy of the lowiron diet to produce TfR upregulation in animals included in the optogenetic-microdialysis experiments was confirmed in parallel control groups of animals fed with the 2 different diets. Demonstration of the same decrease in hematocrit content was then used to demonstrate the same efficacy of the low-iron diet in this experimental group.
Surgical Procedures
Four weeks before the microdialysis experiments, the animals, weighing 80 to 100g, were anesthetized with 3ml/kg of Equithesin (4.44g of chloral hydrate, 0.972g of Na pentobarbital, 2.124g of MgSO4, 44.4ml of propylene glycol, 12ml of ethanol, and distilled H2O up to 100ml of final solution; NIDA Pharmacy, Baltimore, MD). A unilateral injection of an adenoassociated virus (AAV) encoding channelrhodopsin 2 (ChR2) fused to enhanced yellow fluorescence protein (EYFP) under control of the CaMKII neuronal promoter (AAV-CaMKIIahChR2[H134R]-EYFP; University of North Carolina core vector facility) was delivered in the agranular motor cortex; coordinates of injection were 2.5mm anterior, 3mm lateral, and 25mm ventral with respect to bregma). Virus (0.5 ll of purified and concentrated AAV; 1 3 10 12 infectious units/ml) was injected using a 105 lm-thick silica tubing injector coupled directly to a 1 ll syringe driven by an infusion pump. Virus suspension was injected over a 10-minute period at a rate of 50nl/min, and the injector was left in place for an additional 10 minutes to allow diffusion of the suspension. Four weeks after virus injection, with the rats weighing 250 to 325g, a modified microdialysis probe (optogenetic-microdialysis probe) with an embedded light-guiding optic fiber (see below and Quiroz et al 21 ) was implanted into the lateral striatum under Equithesin anesthesia (3ml/kg); coordinates were 0mm anterior, 4.5mm lateral, and 27mm ventral with respect to bregma. The probes were fixed to the skull with stainless steel screws and dental glass ionomer cement.
Intracranial Optogenetic Stimulation
An optogenetic-microdialysis probe with a 125 lm-diameter optic fiber (0.22 numerical aperture) embedded in a microdialysis probe was used for optogenetic stimulation of glutamate release by corticostriatal terminals. 21 The tip of the optic fiber was given a conical shape to allow a local light dispersion through and around the working portion of the dialyzable membrane. The conical sculpted tip with the cladding fused to the core was obtained by pulling the fiber with a FlammingBrown pipette puller (Sutter Instruments, Novato, CA), fitted with a custom platinum heating filament of circular crosssection (1mm in diameter) and a holder designed for the small diameter of the optic fiber. Optical stimulation was delivered coupling the light guiding port of the implanted optogeneticmicrodialysis probe to a 473nm solid-state laser module driven by the electrical stimulator (Grass S88 stimulator; Grass Instrument Co, West Warwick, RI). Light was applied over a 20-minute period in 160-millisecond trains of 1-millisecond pulses at 100Hz at 5 to 8mW at the probe tip (1 train/s). Light intensity at the probe tip was measured before implantation using an integrating sphere silicon photodiode power sensor designed for optical power measurements independent of beam shape and divergence (model S144C; Thorlabs, Newton, NJ).
In Vivo Microdialysis
Microdialysis sampling was performed during optogenetic stimulation to analyze the extracellular concentrations of striatal glutamate of freely moving rats 24 hours after probe implantation. An artificial cerebrospinal solution (aCSF; 144 NaCl, 4.8 KCl, 1.7 CaCl2, and 1.2 MgCl2, in mM) with or without the dopamine receptor agonists pramipexole or ropinirole (1 lM), the a 2 d ligand gabapentin (1 lM) and the selective D4R antagonist L745-870 (10 lM), the nonselective D2R-D3R antagonist raclopride (10 lM), or the selective D3R antagonist VK4-116 (10 lM) was pumped through the optogenetic-microdialysis probe at a constant rate of 1 ml/min. After a washout period of 90 minutes, dialysate samples were collected for 60 minutes of baseline sampling at 20-minute intervals. After baseline sampling, optogenetic stimulation was applied for 20 minutes and 20-minute samples were taken for 80 additional minutes after the beginning of the stimulation. Glutamate content was measured by high-performance liquid chromatography (HPLC) coupled to a glutamate oxidase enzyme reactor and electrochemical detector (Eicom, San Diego, CA). Estimation of diffusion of the compounds through the optogenetic-microdialysis probe was assessed by in vitro recovery. Probes were placed in an Eppendorf tube containing 1ml of a 10 mM concentration of either L745-870, raclopride, or 
Results
Effect of BID on Optogenetically Induced Corticostriatal Glutamate Release
In the parallel groups for control of low-iron diet efficiency, the hematocrit content (expressed as percentage of total volume) from animals with and without low-iron diet was, in mean 6 standard error of the mean (SEM), 18.1 6 1.0% and 47.7 6 0.5% (n 5 20/group), respectively. In the lowiron diet group, striatal TfR density showed a significant increase of 23.7 6 2.9% (p < 0.001; unpaired t test). In the 2 groups included in the optogenetic-microdialysis experiments, the hematocrit content from animals with and without low-iron diet was, in mean 6 SEM, 17.8 6 0.8% (n 5 30) and 47.8 6 0.3% (n 5 22), respectively In our previous studies with the in vivo optogenetic-microdialysis approach, we studied the ability of corticostriatal terminals in the ventromedial striatum to release glutamate upon optogenetic stimulation. 21, 22 In the present study, we aimed at a more motor-involved striatal area, the dorsal striatal area that receives innervation from the agranular motor cortex (Fig 1A) . This corticostriatal projection has been anatomically well defined from different studies analyzing striatal neuronal activation upon cortical-electrical stimulation. 19, 26, 27 A significant glutamate release could be obtained in both irondeprived animals and controls when using a frequency of stimulation of 100Hz (see Fig 1D) , found to be optimal in previous studies of cortical-electrical and striatal optogenetic stimulation. 19, 21, 26 Importantly, when decreasing the frequency of stimulation to 60Hz, a significant glutamate release could only be observed in the rats with iron deficiency (see Fig 1E) . These results therefore confirmed our hypothesis of a higher sensitivity of corticostriatal terminals to depolarization-induced glutamate release in the rodent brain with iron deficiency.
Inhibition of Optogenetically Induced
Corticostriatal Glutamate Release by the Adenosine A 2A Receptor Antagonist MSX-3, the Dopamine Receptor Agonists Pramipexole and Ropinirole, and the a 2 d Ligand Gabapentin
We have recently shown that the optogenetic-microdialysis method allows the study of the functional role of a G protein-coupled receptor localized in striatal glutamatergic terminals in the modulation of glutamate release. 21, 22 It could then be demonstrated that adenosine A 2A receptors (A2ARs) play a strong facilitatory role, because perfusion through the microdialysis probe of the selective A2AR antagonist MSX-3 completely counteracted optogenetically induced corticostriatal glutamate release. 21 In agreement with a functional upregulation of A2AR being involved with the increased sensitivity of corticostriatal terminals induced by BID (see Discussion, Ferr e et al, 8 and Quiroz et al 19 ), perfusion of MSX-3 (1 lM) counteracted glutamate release induced by optogenetic stimulation both in controls (at 100Hz) and in iron-deprived animals (at 60Hz; Fig 2A) . We could then confirm that perfusion of clinically efficient RLS drugs, either the dopamine agonists pramipexole or ropinirole (1 lM in both cases) or the a 2 d ligand gabapentin (1 lM), blocked glutamate release induced by optogenetic stimulation, both in controls (at 100Hz) and in animals with BID (at 60Hz; see Figs 2B-D). 
Effect of D 2 -Like Receptor Antagonists on Pramipexole-Mediated Inhibition of Optogenetically Induced Corticostriatal Glutamate Release
We then questioned the identity of the dopamine receptor subtypes involved in the pharmacological effect of the dopamine receptor agonists. We have recently reported results obtained with the optogenetic-microdialysis technique in knockin mice expressing the long intracellular domain of D4.7, the product of a polymorphic variant of the D4R gene (DRD4) associated with attention deficit hyperactivity disorder. 22 When compared with the wild-type mouse D4R, the expanded intracellular domain of the humanized D4R conferred a gain of function, blunting optogenetically induced corticostriatal glutamate release. 22 These results confirmed a key role of striatal D4R localized in glutamatergic terminals in the control of corticostriatal transmission. In addition, previous studies have also shown evidence for the presence of D2R, particularly its short isoform (D2SR), in striatal glutamatergic terminals and their involvement in the control of glutamate release, 28 possibly by establishing molecular and functional interactions with D4R. 29 Three D 2 -like receptor antagonists were then chosen to disclose the possible contribution of D4R and D2SR in the effect of pramipexole: L745-870, with selective high affinity for D4R [30] [31] [32] ; raclopride, with high affinity for D2R and D3R but low affinity for D4R 31, 32 ; and VK4-116, a recently introduced compound with selective high affinity for D3R. 25 The in vitro recovery of these compounds through the optogenetic-microdialysis probe at the same flow rate used in the in vivo experiments (1 ml/min), as analyzed by HPLC (see Materials and Methods), was 12.0 6 0.7%, 8.2 6 0.2%, and 20.6 6 0.6% for L745-870, raclopride, and VK4-116, respectively. These figures provide an approximation to the effective extracellular concentration of drugs administered through the microdialysis probe (reverse dialysis). Thus, in vivo recovery should be lower than the in vitro recovery because of reduced fluid volume, increased tortuosity, and several other factors. 33 The concentration of the D 2 -like receptor antagonists in the perfusion media (10 lM) should therefore yield extracellular concentrations around the probe of around 1 lM or lower, which would be insufficient for L745-870 to bind significantly to D2R or D3R, for raclopride to bind to D4R, and for VK4-116 to bind to D2R or D4R. 25, [30] [31] [32] Coperfusion with 10 lM of L745-870 or raclopride, but not VK4-116, significantly counteracted the effect of pramipexole (1 lM), and the optogenetic stimulation could still increase glutamate release both in controls (at 100Hz) and in animals with BID (at 60Hz; Fig 3A, B) . The results therefore imply a participation of both D4R and D2SR, but not D3R, in the effect of pramipexole.
Discussion
The present study first demonstrates that BID in rodents is associated with hypersensitive corticostriatal terminals, which show an increased sensitivity to depolarizationinduced glutamate release. An association between iron deficiency and RLS was originally identified by Nordlander in the 1950s. 34 Further studies showed a higher prevalence of RLS symptoms in conditions that compromise iron availability. 35 A recent study in a population of patients with iron-deficiency anemia reported finding a 31.5% prevalence of RLS, 36 which is 6 times higher than the general U.S. population prevalence for RLS. 1 Most patients with RLS, however, do not have systemic iron deficiency. Nevertheless, as already proposed by Nordlander, 34 an iron insufficient state exists in the brains of RLS patients, and all studies of central nervous system iron have consistently shown BID in RLS (see introductory section). This brain-specific deficit in iron may be a consequence of the tight regulation of iron transportation by the blood-brain barrier. 5 In rodents, BID can be consistently induced by providing a severe iron-deficient diet during the postweaning period. Although it does not show motor alterations that would imitate PLMS, the postweaning, diet-induced BID rodent represents a wellaccepted pathophysiological model of RLS. 5, 12, 37 It provides a biological model for the understanding of the iron-dopamine connection in RLS, because it reproduces the main alterations in dopaminergic transmission observed in RLS patients. Those include an increase in striatal extracellular concentrations of dopamine, a reduction in the density of striatal D2R, and increased tyrosine hydroxylase activity in the ventral midbrain. 18, 37 In view of the validity of the rodent with BID as a pathogenetic model of RLS, the present results imply that hypersensitive corticostriatal terminals might represent a key mechanism responsible for the deficit of sensorimotor integration responsible for PLMS in RLS. That being the case, it would be expected that drugs with clinical efficacy for PLMS in RLS target corticostriatal terminals, counteracting depolarization-induced glutamate release. The 2 classes of drugs used as a first alternative in RLS, dopamine agonists and a 2 d ligands, 6 were very effective at counteracting optogenetically induced glutamate release by both normal and hypersensitive corticostriatal terminals.
In previous studies, we provided evidence for alterations in adenosine neurotransmission in rats with BID, which could represent a main factor responsible for the increase in the sensitivity of corticostriatal terminals. Those changes led us to hypothesize, first, that rodents with BID should show hypersensitive corticostriatal terminals, and second, that this could represent a main pathogenetic factor in the development of PLMS in RLS. 8, 19 Specifically, we found functional upregulation of A2AR and downregulation of adenosine A 1 receptors (A1Rs). 19, 20 In the striatum, both receptors are colocalized presynaptically in glutamatergic terminals, where they form A1R-A2AR heteromers that finely modulate glutamate release. 38, 39 Because activation of A1R and A2AR lead to the opposite effect, inhibition and facilitation of striatal glutamate release, 38, 39 upregulation of A2AR and downregulation of A1R would be expected to increase sensitivity of corticostriatal terminals to release glutamate, decreasing the filtering of multiple cortical signals that converge in the striatum and therefore impairing striatal sensory-motor integration (Fig 4) . In the present study, blockade of A2AR with the perfusion of a selective antagonist also counteracted optogenetically induced glutamate release by both normal and hypersensitive corticostriatal terminals. These results would predict that A2AR antagonists could be useful in RLS. However, the highest density of striatal A2AR is found postsynaptically, in the c-aminobutyric acidergic striatopallidal neurons, and postsynaptic A2AR was also found FIGURE 4: Schematic representation of a corticostriatal glutamatergic terminal and modulatory dopamine and adenosine receptors. Dopamine and adenosine modulate corticostriatal glutamate (GLU) release by acting on adenosine A1R-A2AR and dopamine D2R-D4R heteromers. The A1R-A2AR heteromer acts as an adenosine concentrationdependent switch, by which a low adenosine concentration activates preferentially A1R, which produces inhibition of glutamate release, and a high adenosine concentration also activates A2AR, which shuts down A1R signaling and promotes an A2AR-mediated stimulation of glutamate release. The D2R-D4R heteromer provides a dopamine concentration-dependent stepwise inhibitory mechanism of glutamate release that depends on the higher affinity of dopamine for the D4R and on a D4R-mediated increase of D2R signaling. The brain iron deficiency-dependent increase in the excitability of the glutamatergic terminal to release glutamate seems to depend on functional downregulation of A1R and upregulation of A2AR, which can be counteracted by A2AR antagonists D2R or D4R agonists and a 2 d ligands (see text). The function of voltage-dependent calcium channels (VDCCs), the activation of which promotes vesicular fusion and neurotransmitter release, is regulated by Gi-coupled receptors (ßc-mediated inhibition), including A1R, D2R, and D4R, as well as by accessory a 2 d subunits, the targets of gabapentinlike compounds. ChR2 5 channelrhodopsin 2 (see text).
to be upregulated in rats with BID. 19 Unfortunately, blockade of postsynaptic A2AR could be expected to increase RLS symptomatology by potentiating postsynaptic D 2 receptor long isoform (D2LR) signaling (see below). Nevertheless, striatal postsynaptic A2AR forms heteromers with D2LR, and it has already been established that heteromerization can determine changes in the affinity of ligands, offering a strategy for ligand selectivity. 40 By screening several A2AR antagonist, we found that the A2AR antagonist SCH-442416 shows lower affinity for postsynaptic A2AR (A2AR-D2LR heteromers) than for presynaptic A2AR (A1R-A2AR heteromers). 39 Presynaptic A2AR antagonists have not yet been introduced into the clinic, but they could provide a new treatment for RLS. Different from a 2 d ligands, like gabapentin, which are already assumed to act by decreasing glutamatergic neurotransmission, the ability of the dopamine agonists pramipexole and ropinirole to strongly modulate the function of corticostriatal glutamatergic terminals implies a conceptual change in their generally assumed therapeutic mechanism. Pramipexole and ropinirole are ligands with preferential affinity for D 2 -like versus D 1 -like receptors and, among the different D 2 -like receptor subtypes, they both have preferential affinity for D3R, as compared to D2SR, D2LR, and D4R. [41] [42] [43] This has led to the assumption that D3R is the main target involved in the therapeutic effect of dopamine receptor agonists in RLS. 44, 45 However, as mentioned by Varga et al, 44 it remained to be determined whether the relative D3R selectivity of pramipexole and ropinirole had pharmacological relevance at the doses used clinically. The present study does not support the D3R hypothesis. First, striatal D3Rs are only localized postsynaptically, 46 indicating that they cannot target corticostriatal glutamate terminals. Instead, dopamine D2SR and D4R are the D 2 -like receptor subtypes preferentially localized in corticostriatal glutamatergic terminals and involved in a direct modulation of striatal glutamate release (see Fig 4) . 22, 28, 29 The ability of pramipexole to counteract optogenetically induced glutamate release in rats with BID and in controls was counteracted by the selective D4R antagonist L745-870 and by raclopride, a D 2 -like receptor antagonist with very low affinity for D4R, whereas it was not modified by the selective D3R antagonist VK4-116. The present results suggest that searching for more selective D2SR and D4R agonists could be a promising strategy for treating RLS. D4R can be particularly seen as the main therapeutic target, because it is more selectively expressed by corticostriatal neurons than D2SR and it has been recently shown to play a main role as a mediator of dopamine modulation of corticostriatal neurotransmission. 22 Conversely, D2SR has a more widespread expression, including the dopamine cells, where it acts as autoreceptor. 47 In addition, a selective D2SR ligand devoid of activity for the striatal postsynaptic D2LR might be difficult to obtain. Activation of D2LR might contribute to unwanted side effects in RLS, such as augmentation of the symptoms upon prolonged treatment with dopamine receptor agonists. The clinical study by Manconi et al, 45 which finds a much higher efficacy of pramipexole as compared to bromocriptine in RLS, can be quite demonstrative of the therapeutic value of D4R ligands. Thus, although the results were interpreted as related to the different affinities for D3R, the most dramatic pharmacological difference between both drugs is the very low affinity of bromocriptine for D4R. 43 In summary, the present study provides preclinical evidence for a main pathogenetic mechanism of PLMS in RLS, hypersensitive corticostriatal glutamatergic terminals. It also provides a plausible explanation for the previously unknown common mechanism responsible for the therapeutic effect of a 2 d ligands and dopamine receptor agonists in RLS, the inhibition of corticostriatal glutamate release. Finally, these data support a switch in the dopamine receptor subtype as a therapeutic target for RLS from the D3R to the D4R. This switch implies the need for further investigation of selective D4R agonists for the treatment of RLS.
